1Q23 Business Results

YuflymaⓇ ✓ Prescription of the product has been increased due to its competitive product advantage with diverse strength and device options provided in the EU ✓ Will be launched in the US market in 2H23; currently in the process of discussion with the stakeholders including PBM and GPO etc. Global market size of Adalimumab 80% Global Adalimumab Market Size $34.6bn Competitive Edge of YuflymaⓇ ✓ 85% of the market taken by high-concentration in the US High Concentration ✓ Improving patient convenience by reducing administration time A global interchangeability 13% 7% phase 3 clinical trial ongoing Interchange- ability Yuflyma adalimumab Strength Variation EMA approved for 40mg/0.4ml & 80mg/0.8ml ✓ EMA application for 20mg/0.2ml submitted FDA application for 40mg/0.4ml submitted US ■ Europe ROW Note: Market size is as of 2022 Source: IQVIA Citrate & Latex-Free: Reducing pain & allergic reactions following injection Reduce Injection Device Variation Pain Over 90% prescribed Al type in the US The only BS having 80mg/0.8ml Al type Investor Relations 2023 11 1Q23 Business Results Key Products Plan & Vision Appendix

View entire presentation